Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Freeline

31.03.2021

Freeline to Present at Upcoming Investor Conferences (1)

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences:
Freeline

11.03.2021

Freeline Appoints Colin Love, PhD to Board of Directors

Experienced biopharmaceutical executive with established record of successfully developing, manufacturing and launching impactful therapies.
Freeline

02.03.2021

Freeline to Present at Upcoming Investor Conferences

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today that Theresa Heggie, Chief Executive Officer, will present a company overview at the following virtual investor conferences in March:
Freeline

16.02.2021

Freeline Announces Expansion of Executive Leadership

Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments. Chief Financial Officer Brian M. Silver leaving Freeline to pursue a new opportunity
Freeline

09.02.2021

Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that it will deliver one oral and three e-poster presentations at the 17TH Annual WORLDSymposium™ taking place virtually from February 8 – 12, 2021, highlighting data from its gene therapy programs in Gaucher and Fabry diseases.
Freeline

26.01.2021

Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021.
Freeline

04.01.2021

Freeline to participate at Conferences during January 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021.
Freeline

19.11.2020

Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that management will participate in a fireside chat at the 3rd Annual Evercore ISI Health CONx Conference on 3 December, 2020 from 08.00 – 8.20 am ET.
Freeline

02.11.2020

Freeline appoints Mark Baldry as Chief Commercial Officer

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced that Mark Baldry, MBA, has today been appointed as the Company’s new Chief Commercial Officer, effective from today’s date.
Freeline

30.10.2020

Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, liver directed, AAV-based gene therapy company today announced its financial results for the first half of 2020 and provided a business update.

Load More